Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Weekly Ratings on May 16, 2018

May 16, 2018 - By Joshua Cleveland

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.22. That’s change of 0.01, from 2017Q3’s 1.21. 19 investors sold all, 48 reduced holdings as Agios Pharmaceuticals, Inc. ratio improved. 55 grew holdings while 27 funds took holdings. Funds hold 45.70 million shares thus 2.27% more from 2017Q3’s 44.69 million shares.
Amalgamated National Bank invested in 0.01% or 8,287 shs. Swiss National Bank reported 70,060 shs. Voya Inv Limited Liability Co invested in 14,886 shs or 0% of the stock. Columbia Wanger Asset Management Lc holds 0.65% or 760,116 shs in its capital. 24,200 were accumulated by Gam Holdings Ag. Sei Invests reported 2,869 shs or 0% of all its holdings. Eaton Vance Mgmt owns 98,621 shs for 0.01% of their capital. Principal Group Inc reported 0% stake. Stratos Wealth Prtn Ltd owns 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 200 shs. Deutsche Financial Bank Ag has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Capital Sarl invested in 0.17% or 32,600 shs. Invesco Ltd reported 0.02% of its capital in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). D E Shaw has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Trexquant Investment L P holds 3,690 shs. State Of Alaska Department Of Revenue holds 2,800 shs or 0% of its capital.

Agios Pharmaceuticals, Inc. registered $18.55 million net activity with 1 insider buy and 23 insider sales since January 10, 2018. 2,050 shs were sold by Hoerter Steven L., worth $173,533 on Thursday, March 22. Bowden Christopher sold $157,500 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, February 1. On Friday, January 12 Shares for $161,250 were sold by Alenson Carman. 200 shs were bought by Scadden David, worth $16,688 on Friday, March 16. Biller Scott sold $195,000 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Wednesday, January 10. Another trade for 6,800 shs valued at $557,396 was made by Foster-Cheek Kaye I on Monday, March 19.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Total analysts of 4 have positions in Agios Pharma (NASDAQ:AGIO) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 19, 2017 according to StockzIntelligence Inc Agios Pharma has 5 analyst reports. The company rating was maintained by Credit Suisse on Thursday, February 15. On Wednesday, February 14 the firm earned “Buy” rating by RBC Capital Markets. The company rating was maintained by Credit Suisse on Wednesday, April 11. On Thursday, February 15 the rating was maintained by JP Morgan with “Overweight”. On Sunday, November 19 the stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by SunTrust. Listed here are Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PTs and latest ratings.

11/04/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $80 New Target: $95 Maintain
15/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $76 New Target: $85 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $80.0 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $88.0 Maintain
19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain

AGIO hit $86.23 during the last trading session after $0.79 change.Currently Agios Pharmaceuticals, Inc. is uptrending after 41.40% change in last May 16, 2017. AGIO has 53,492 shares volume. AGIO outperformed the S&P500 by 29.85%.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States.The company has $4.97 billion market cap. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML.Currently it has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

For more Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news published recently go to: Streetinsider.com, Benzinga.com, Streetinsider.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Agios Pharma (AGIO) PT Raised to $90 at RBC Capital” published on May 07, 2018, “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” on April 29, 2018, “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” with a publish date: May 15, 2018, “A Fresh Look At Celgene After Q1 And New Info On Ozanimod” and the last “Agios Pharmaceuticals (AGIO) Investor Presentation – Slideshow” with publication date: May 04, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.